Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406662 | 0.88 | ALDH1A1 (0.46) | ALDH1A1MAPTLMNAPOLBCYP1A2 | |
| SCHEMBL4991 | 0.78 | TSHR (0.48) | ALDH1A1LMNACYP1A2MEN1CYP3A4 | |
| SCHEMBL29352520 | 0.78 | TSHR (0.48) | ALDH1A1LMNACYP1A2MEN1CYP3A4 | |
| SCHEMBL4129 | 0.77 | TSHR (0.47) | ALDH1A1MAPTLMNAENPP2TSHR | |
| SCHEMBL29404220 | 0.77 | TSHR (0.47) | ALDH1A1MAPTLMNAENPP2TSHR | |
| SCHEMBL215780 | 0.76 | TSHR (0.41) | ALDH1A1LMNACYP1A2ENPP2CYP2A6 | |
| SCHEMBL112040 | 0.76 | — | — | |
| SCHEMBL29479067 | 0.75 | TRPA1 (0.50) | ALDH1A1MAPTCYP1A2ENPP2CYP2A6 | |
| Benzene SCHEMBL28042388 | 0.75 | LMNA (0.45) | ALDH1A1LMNAENPP2CYP2A6TSHR | |
| SCHEMBL309076 | 0.75 | TRPA1 (0.50) | ALDH1A1MAPTCYP1A2ENPP2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4663626-A1 | IMINE COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Bio Genuine (Shanghai) Biotech Co., Ltd (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250255848-A1 | SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2025-08-14 | — | — | US | disclosed |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| CN-1370176-A | Subsstituted heterocycle fused gamma-carbolines | BRISTOL MYERS SQUIBB CO (US) | 2002-09-18 | — | — | CN | disclosed |
| EP-1212303-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1192165-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1189905-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-03-27 | — | — | EP | disclosed |
| US-20020019393-A1 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED | 2002-02-14 | — | — | US | disclosed |
| WO-2001016108-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-1077943-A1 | HETEROCYCLIC INHIBITORS OF P38 | Vertex Pharmaceuticals Incorporated (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000077001-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-1999058502-A1 | HETEROCYCLIC INHIBITORS OF P38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | CD274, PDCD1LG2, PDCD1 | ALDH1A1 1759/4885MAPT 4007/4885LMNA 4333/4885 |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | ALDH1A1 223/4885MAPT 4685/4885LMNA 4857/4885 |
| US-12378243-B2 | Quinoline compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | ALDH1A1 1858/4885MAPT 4504/4885LMNA 2409/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | ALDH1A1 1816/4885MAPT 4652/4885LMNA 4684/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | ALDH1A1 3259/4885MAPT 2197/4885LMNA 3885/4885 |
| US-20020019393-A1 | Inhibitors of p38 | MAPK1, MAPK3, MAP3K1 | ALDH1A1 3189/4885MAPT 1883/4885LMNA 2007/4885 |
| US-20250255848-A1 | SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | CYP19A1, FSHR, GPER1 | ALDH1A1 637/4885MAPT 4606/4885LMNA 2311/4885 |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | ALDH1A1 2204/4885MAPT 4509/4885LMNA 2478/4885 |
| US-20250368641-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | ALDH1A1 1858/4885MAPT 4504/4885LMNA 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.